ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 456

Vitamin D Is Not Associated with Treatment Responses in Patients with Newly Diagnosed Rheumatoid Arthritis

Juyeon Kang 1 and Chan-Bum Choi1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis (RA) and 25-hydroxyvitamin D

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Vitamin D is known to have immunomodulatory properties and had shown a relationship with susceptibility and disease activity in rheumatoid arthritis (RA). We investigated the relationship between response to treatment and vitamin D levels in patients newly diagnosed with RA.

Methods: This was a retrospective study of 249 patients who were newly diagnosed with RA. They were assessed for 25-hydroxyvitamin D (25OHD) level at diagnosis of RA and after 6 months of treatment. All patients with vitamin D insufficiency (25OHD < 30 ng/ml) received vitamin D supplementation. Correlation between vitamin D levels and disease activity measured by Disease Activity Score 28 calculated with erythrocyte sedimentation rate (DAS28-ESR) at diagnosis and after 6 months were assessed.

Results: The proportion of patient with low, moderate, and high disease activity at diagnosis were 9.2%, 59.4%, and 31.3%, respectively. Mean level of 25OHD was 18.8 ± 11.3 ng/ml. Vitamin D level showed no significant correlation with disease activity at diagnosis with a mean 25OHD value of 17.4 ± 8.6 ng/ml, 19.1 ± 11.3 ng/ml, and 18.8 ± 12.1 ng/ml, respectively. After 6 months of treatment, the proportion of patients in remission, low, moderate, high disease activity were 41.7%, 22.4%, 29.4%, and 6.1%, respectively. Vitamin D significantly increase to mean 25OHD value of 24.7 ± 11.1 ng/ml after 6 months of treatment of RA and vitamin D supplementation in patients with insufficiency. However, it showed no significant correlation with treatment response at 6 months with a mean value of 23.2 ± 11.4 ng/ml, 25.1 ± 10.5 ng/ml, 26.2 ± 10.5 ng/ml, and 26.3 ± 11.9 ng/ml.

Conclusion: Patients showed vitamin D insufficiency at diagnosis of RA, but vitamin D was not correlated with treatment response of RA.


Disclosure: J. Kang, None; C. Choi, Eisai Korea, 2.

To cite this abstract in AMA style:

Kang J, Choi C. Vitamin D Is Not Associated with Treatment Responses in Patients with Newly Diagnosed Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/vitamin-d-is-not-associated-with-treatment-responses-in-patients-with-newly-diagnosed-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vitamin-d-is-not-associated-with-treatment-responses-in-patients-with-newly-diagnosed-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology